Xiaole Liu (刘小乐), Ph.D.
Director, Center of Functional Cancer Epigenetics, Dana-Farber Cancer Institute; Associate Member, Broad Institute of Harvard and MIT
Research Interests : Precision medicine, computational biology, cancer epigenetics, immunology, immunotherapy, CRISPR screens
Xiaole Shirley Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University. Her research focuses on algorithm development and integrative modeling of high throughput genomic data to understand the specificity and function of regulator genes in tumor development, progression, drug response and resistance. She is especially interested in genomics and bioinformatics approaches in cancer epigenetics, cancer immunology, and CRISPR screens for translational cancer research. Her lab developed widely used algorithms for transcription factor motif discovery, ChIP-chip/seq, CRISPR screen, and immune repertoire data analysis. Her computational modeling helped the understanding of ER, AR, FoxA1, XBP1, EZH2, PBAF regulation as well as BET bromodomain inhibitor, gamma secretase inhibitor, CDK4/6 inhibitor, and immune checkpoint inhibitor function in different cancers. Dr. Liu is a member of the ENCODE consortium from NHGRI and the lead investigator for the Cancer Immune Data Common from NCI. She has an H-index of 77 and has published over 50 papers in Nature, Science or Cell series journals. She is the recipient of the Sloan Research Fellowship, the Richard E. Weitzman Award from the Endocrine Society, the Claire W. and Richard P. Morse Research Award, the Breast Cancer Research Foundation Investigator, and Yangtze River Scholar and 1000 Talent Scholar in China. Over the last decade, she has successfully mentored sixteen trainees to start tenure track faculty positions.